UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 86 filers reported holding UROGEN PHARMA LTD in Q2 2019. The put-call ratio across all filers is 0.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $42,000 | -68.4% | 2,369 | -40.6% | 0.02% | -60.9% |
| Q4 2019 | $133,000 | -62.7% | 3,987 | -73.4% | 0.05% | -65.7% |
| Q3 2019 | $357,000 | -33.8% | 15,000 | 0.0% | 0.13% | -34.0% |
| Q2 2019 | $539,000 | -2.7% | 15,000 | 0.0% | 0.20% | -15.1% |
| Q1 2019 | $554,000 | -14.2% | 15,000 | 0.0% | 0.24% | -25.5% |
| Q4 2018 | $646,000 | -8.8% | 15,000 | 0.0% | 0.32% | +10.3% |
| Q3 2018 | $708,000 | +42.2% | 15,000 | +50.0% | 0.29% | +24.9% |
| Q2 2018 | $498,000 | +122.3% | 10,000 | +122.2% | 0.23% | +113.8% |
| Q1 2018 | $224,000 | – | 4,500 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
| Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
| Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
| AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
| Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
| EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
| RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
| Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |